About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox for Relapsed/Refractory Disease & Concurrent Rituximab with Cladribine for 1st Line
By
KU Hematology & Medical Oncology Review 2019
FEATURING
Abdulraheem Yacoub
By
KU Hematology & Medical Oncology Review 2019
FEATURING
Abdulraheem Yacoub
60 views
August 2, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Related Content
AUTOPLAY
ON
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
10:49
Monia Marchetti
Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…
31:02
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
Detangling New Approaches to Hairy Cell Leukemia - A Comb or a Brush?
Feat.
D. Hermel
12:27
MyCancerHaven
Experts Discuss the Basics of Diagnosis and Treatment of Hairy Cell …
Feat.
R. Vij,
L. Andritsos
12:47
2019 Scripps MD Anderson's Oncology Update
Lymphoma Practicing Changing ASCO19 Studies: Novel Agents Prior to R…
Feat.
A. Saven
25:01
Indy Hematology Review
Review of Emerging Therapies and Top Trials in Hematologic Malignanc…
Feat.
R. Birhiray
07:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
French National Retrospective Cohort of Hairy-Cell Leukemias: Risk o…
Feat.
J. Paillassa
22:37
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…
Feat.
T. Badar
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
12:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"
Feat.
S. O'Brien,
C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute
Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…
Feat.
A. Winter
04:16
Luke Fletcher
Efficacy and Safety of Asciminib in Ph+ CML
50:34
Scripps MD Anderson Cancer Center
The Cure of Leukemias in the Next Decade: An Optimist’s View
Feat.
H. Kantarjian
06:00
2024 Clinical Case Studies
Clinical Case Review: A Not-So-Sweet Case of Vulvar Ulceration
Feat.
A. Geisler
06:53
UC Irvine Health
Fixed-Duration Treatment in CLL: Current Considerations
Feat.
E. Brem
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
Feat.
R. Gale
24:33
Indy Hematology Review
Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…
Feat.
J. Woyach
